We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-... Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018 for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease. Show more
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 Exploring opportunities to expand KPI-012 into additional corneal indications Cash...
0001479419false00014794192024-03-042024-03-04UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 8-KCURRENT REPORTPursuant to Section 13 or 15(d)of the...
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ...
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.03 | -0.375 | 8 | 8 | 7.6431 | 13777 | 7.92447109 | CS |
4 | 0.79 | 11.0027855153 | 7.18 | 8 | 7.03 | 17484 | 7.61786279 | CS |
12 | 1.15 | 16.862170088 | 6.82 | 9.25 | 6.43 | 30036 | 7.64656594 | CS |
26 | -1.02 | -11.3459399333 | 8.99 | 10.97 | 5.1 | 49721 | 8.02141989 | CS |
52 | -6.9 | -46.4021519839 | 14.87 | 19.5699 | 5.1 | 65119 | 12.70664422 | CS |
156 | -345.03 | -97.7422096317 | 353 | 419.21 | 3.5444 | 1142816 | 101.64815967 | CS |
260 | -376.53 | -97.9271781534 | 384.5 | 734 | 3.5444 | 1092886 | 211.47543369 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions